Specialty Generics Market Size Worth $174.9 Billion By 2025

The global specialty generics market is expected to reach USD 174.9 billion by 2025, according to a new report by Grand View Research, Inc. Rise in demand for low-cost generic specialty drugs is a major factor estimated to accelerate the market growth during the forecast period. Introduction of cost-effective drugs for the treatment of multiple sclerosis, cancer, and other infectious diseases is expected to showcase huge opportunities for the specialty generic drug manufacturers. According to U.S. FDA, generic drugs cost 80% to 85% lower as compared to branded drugs. One of the factors contributing to their affordable price is that they do not need to repeat expensive clinical trials, advertising, and promotional activities. Thus, low cost of generic specialty drugs is expected to accelerate the demand for these medicines.

Rise in number of off-patent specialty drugs is another major factor expected to support growth of the specialty generic drugs market. For instance, the patent for Gilenya, a blockbuster drug by Novartis, will expire in 2019. This drug led to USD 3.1 billion in sales in 2016 for Novartis, with 14% sales growth. In April 2017, Novartis failed to acquire patent extension for Gilenya till 2026 in the U.S. Federal Circuit. Such early patent expirations are expected to boost the entry of new generics.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/specialty-generics-market

Further Key Findings From the Report Suggest:

In 2016, injectables was the largest revenue-grossing segment in the market due to its high usage and efficacy in treatment of severe chronic diseases
The oncology segment accounted for the largest revenue share in 2016 and is expected to maintain its dominance during the forecast period due to worldwide rise in cancer prevalence
The specialty pharmacy was the largest revenue-generating segment in end use and is estimated to maintain its dominance during the forecast period. This is due to the fact that specialty pharmacies are dedicated to distribution of highlycomplex, costly, and high-touch medicine
North America dominated the total market in 2016 primarily due to the presence of highly developed healthcare infrastructure and local presence of large number of established pharmaceutical companies
The Asia Pacific market is estimated to grow at the highest growth rate during the forecast period. Rising prevalence of chronic diseases, developing healthcare infrastructure, and escalating disposable income in Asian countries, such as China and India, are major factors that can be attributed to the growth
Some of the major players are Teva Pharmaceuticals USA, Inc.; Mylan N.V.; Sandoz International GmbH; Akorn, Inc.; Mallinckrodt; Valeant Pharmaceuticals International, Inc.; Pfizer, Inc.; Endo Pharmaceuticals, Inc.; Apotex Corp.; Sun Pharmaceutical Industries Ltd.

Erythropoietin Drugs Market Size Worth $17.4 Billion By 2025

The global erythropoietin drugs market is expected to reach USD 17.4 billion by 2025, according to a new report by Grand View Research, Inc. Rising incidence of chronic diseases such as CKD and cancer resulting in anemia is a major growth driver of this market.

According to the statistics published by the National Heart, Lung, and Blood Institute of the U.S. Department of Health & Human Services, over 3 million people are affected by anemia every year and this number is expected to increase over the forecast period. This showcases the need for erythropoietin-stimulating agents in the coming years.

Introduction of novel drugs and their cheaper biosimilar formulations with enhanced efficacy and cost-effectiveness is also expected to serve this industry with lucrative opportunities. For instance, development of numerous biosimilars in the European market is expected to gain traction and increase their usage rates, owing to associated benefits such as less time required for approval, cost-efficiency, and enhanced therapeutic effect.

Companies are involved in extensive R&D initiatives for development of innovative molecules and discovering new therapeutic areas for existing drugs. For instance, in April 2016, Sandoz received approval from the European Commission for use of its biosimilar Binocrit in nephrology indications, thereby extending the therapeutic area of its product portfolio.

Moreover, many of the industry players in the U.S., Europe, and Asia Pacific are involved in the development of new biosimilars. For example, Biocon’s subsidiary Syngene International entered into an agreement with Bristol-Myers Squibb to extend their drug discovery and development program in India. This enables Biocon to enhance its erythropoietin drugs portfolio. Expected product approvals in the coming years are anticipated to fuel market growth.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/erythropoietin-epo-drugs-market

Further key findings from the report suggest:

The biologics segment is declining over the forecast period owing to patent expiration of branded biologics and introduction of biosimilars in the market
The patent for Aranesp (darbepoetin-alfa) will expire in 2024 in the U.S. and is expected to provide numerous future growth opportunities for new market entrants
Epoetin-alfa held the largest share of product segment owing to its early introduction in the U.S. market and patent protection
Epoetin-omega and epoetin-zeta are anticipated to exhibit lucrative growth over the forecast period owing to associated benefits such as longer half-life and enhanced therapeutic effects
Use of erythropoietin drugs for treatment of renal diseases held a dominant share as of 2016 owing to the increasing incidence of chronic kidney diseases
The Asia Pacific regional industry for erythropoietin-stimulating agents is expected to witness lucrative CAGR during the forecast period
Industry participants are focusing on the discovery of new therapeutic areas for existing drugs and development of cost-effective biosimilars, thereby increasing R&D activities for the development of erythropoietin drugs.

Oncology Based In-Vivo CRO Market Size Worth $1.5 Billion By 2025

The global oncology based in-vivo CRO market is expected to reach USD 1.5 billion by 2025, according to a new report by Grand View Research, Inc. The use of Contract Research Organization (CRO) oncology services helps the manufacturers/sponsors to provide complete attention on the production capacity and at enhancing their in-house processes.

Furthermore, the pressure from the increasing competition due to patent expirations, rapid growth of generics, and introduction of biosimilar equivalents are propelling the pharmaceutical companies to take the aid of such organizations. Hence, it can be predicted that the oncology based in-vivo CRO market may witness lucrative growth over the forecast period.

Another factor propelling growth is the increasing incidence of cancer, and high failure rate of existing treatment options. According to statistics published by the World Health Organization (WHO), approximately 8.2 million deaths are recorded each year from cancer, which accounts for 13.0% deaths worldwide.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/oncology-based-in-vivo-cro-market

Further key findings from the study suggest:

Based on indication, solid tumors are expected to dominate the market as of 2016. Furthermore, it is anticipated to grow at the fastest CAGR owing to the factors such as growing incidence rate, augmenting research for tumors in organs such as breast, and liver, and technological advancement offered by key industry players.
Solid tumors are analyzed by means of models such as xenograft, Patient Derived Xenografts (PDX), and syngeneic. The PDX models are expected to witness lucrative growth over the forecast period and capture over 40.0% of the market share by 2025.
Geographic expansion into Asia Pacific countries by well-established players is anticipated to promote the fastest growth for the region. India is one the most lucrative country owing to presence of service tax exemption and venture capital based funding for CROs.
Few of the industry players for the oncology based in-vivo CRO market are The Jackson Laboratory, Covance, Taconic Biosciences, Charles River Laboratory, EVOTEC, Wuxi AppTec, and ICON Plc.
A common trend observed is the rising partnerships among CROs to offer bundle packages of services to sponsors. For instance, In May 2017, CRL International, Inc. announced their partnership with OcellO, established in Netherlands. According to this partnership, CRL would be utilizing the latter’s PDX model capabilities in order to expand their oncology based drug discovery service portfolio.

Biotechnology/Pharmaceutical Services Outsourcing Market Worth $92.9 Billion By 2025

The global biotechnology services outsourcing market is expected to reach USD 92.9 billion by 2025, according to a new report by Grand View Research, Inc. Pharmaceutical industry has been adaptive of the function of outsourcing certain clinical and corporate functions as early as 2002. Among the services outsourced, clinical trial management and contract manufacturing were the forerunners. For instance, Johnson & Johnson was the first pharmaceutical company to outsource its applications development and maintenance (ADM).

In 2015, over USD 50.0 billion was spent on pharmaceutical R&D activities majorly on oncology, diabetes, and autoimmune therapy classes, which is expected to propel the biotechnology services outsourcing market growth over the forecast period.

Shrinking profit margins coupled with rising competition in the market space, and augmenting regulatory burden are other vital impact rendering factors. The pharmaceutical services outsourcing market is expected to register growth at a CAGR of 8.7% during the forecast period. On the other hand, pending immigration legislations in the U.S. may hinder business economics and outsourcing risks.

Pharmaceutical and biotechnology industries in Europe are significantly investing in R&D in the recent year owing to rising demand for advanced medicines. This may be attributed to increasing aging population, incidence of chronic diseases, and communicable diseases.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/biotechnology-pharmaceutical-services-outsourcing-market

Further key findings from the report suggest:

Consulting services are inclusive of regulatory compliance, remediation, and quality management systems consulting, which is expected to dominate the pharmaceutical services outsourcing market in 2025.
In 2013, the U.S. FDA revised the guidelines for registration trials of drugs used in the treatment of acute bacterial skin and skin structure infections, thereby promoting growth of regulatory affairs services.
Other services such as contract manufacturing, product upgrade, and IT consulting services are projected to grow swiftly. Increasing focus on generic medicine and regional expansions in developing regions are some of the key contributing factors
Presence of cheap labor, skilled personnel and rapid growth of the pharmaceutical industry within the Asia Pacific region presents numerous opportunities for service providers, thereby representing a lucrative growth rate over the forecast period.
Service based expertise may be found in players such QuintilesIMS, Parexel Corporation, Lachman Consultant Services, Inc., Concept Heidelberg GmbH, and others. These players compete on the basis of service quality, competitive pricing, and long-term relations with healthcare industry participants.

Drug And Gene Delivery Systems Market Worth $786.9 Billion By 2025

The global drug and gene delivery systems market is expected to reach USD 786.9 Billion by 2025, according to a new report by Grand View Research, Inc. Rising investment by the market players to develop innovative drug delivery systems to cater to the demand by the patients as well as to increase the bioavailability at minimum quantity of active pharmaceutical ingredient is driving the market growth. Additionally, increasing focus on R&D of gene delivery systems owing to the high growth potential of gene therapy for the treatment of a wide range of diseases is expected to fuel the market growth in the future.

Drug delivery systems are in a constant evolution along with the changing preference by the patient. For instance, initially, hormone replacement therapy was widely prescribed in the form of pills, whereas, it is now available in the form of prefilled syringes, patches, vaginal rings, gel, and sprays. The principal purpose of development of different forms of delivery systems is to increase the ease of use. Factors such as aesthetics of the delivery systems, price, and amount of API are also considered while designing the drug delivery system.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/drug-gene-delivery-devices-market

Further key findings from the study suggest:

The market study suggests that oral segment dominated the market in 2015
The convenience of use and low manufacturing cost are the prime factors responsible for the dominance of the oral delivery segment
Injectable segment is expected to show a lucrative growth rate owing to the introduction of technically advanced injecting devices that enable convenient self-injection
North America dominated the market in 2015 and is expected to remain dominant throughout the forecast period owing to highly developed healthcare infrastructure and high healthcare spending
Asia pacific is expected to exhibit the fastest growth rate during the forecast period owing to the factors such as rapidly developing economies, growing disposable income, and high adaption of the advanced delivery systems
A few of the major market players in drug delivery systems space are F. Hoffmann-La Roche Ltd, Pfizer, Inc., Johnson and Johnson private Ltd, Novartis AG, Becton, Dickinson and Company, and Bayer AG.
Major market players in the gene delivery systems space are SiBiono GeneTech Co., Unique N.V., Epeius Biotechnologies Corporation, Human Stem Cells Institute, and Shanghai Sunway Biotech Co., Ltd.

Ovarian Cancer Drugs Market Size Worth $4.5 Billion by 2022

The global ovarian cancer drugs market size is expected to be valued at USD 4.5 billion by 2022, as per a new report by Grand View Research, Inc., expanding at a CAGR of 23.7% during the forecast period. The growth of the market is largely driven by factors such as increased adoption of novel drugs and presence of strong pipeline. Rising incidence of ovarian cancer due to growing geriatric population and unhealthy lifestyles is providing an upthrust to the market.

Ovarian cancer accounts for 3.0% of all malignant tumors among women and 6.0% of all femaledeaths due to cancer. Ovarian cancer accounted for 235,200 new cases and 140,000 deaths worldwide in 2016 with the highest incidence being reported in North America and Europe.

Introduction of non-platinum based PARP inhibitors and VEGF inhibitors in second and third-line settings has changed the treatment regime for ovarian cancer dramatically. Several biologic and small-molecule therapies including antibody drug conjugates (ADC) in development are estimated to have a major impact on ovarian cancer treatment spectrum.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/ovarian-cancer-drugs-market

Further key findings from the report suggest:

EU5 is projected to be the second largest market with more than 10.0% share in 2022, owing to increasing ovarian cancer incidence and approval of PARP inhibitors
Key players in the industry are focusing on collaborations for development, broader product portfolios, and regional expansion in emerging markets to increase their market share
Combination regimens and pipeline breakthroughs, specifically those including checkpoint inhibitors such as Roche’s Tecentriq and Pfizer’s Bavencio, are poised to be the upcoming milestones for ovarian cancer treatment
PARP inhibitors are anticipated to be the fastest growing drug class in the ovarian cancer market through the forecast period. Factors such as continued uptake of approved PARP inhibitors owing to their superior efficacy, long treatment duration, and considerable number of treatment opportunities in first-line advanced settings are likely to propel the growth of the drug class.
Although angiogenesis inhibitors accounted for the majority of shares in the market in 2016, the drug class is expected to capture a marginal share in 2022 owing to increasing competition from PARP inhibitors and novel pipeline products
Out of 78 drugs in the pipeline for ovarian cancer, 11 drugs are in Phase III, 29 in Phase II and the remaining in Phase I and pre-clinical trials
A greater understanding of tumor microenvironment is estimated to occur, which would further drive successful development of new patient-specific therapies through the forecast period
Late-stage pipeline includes novel drugs such as ImmunoGen’s mirvetuximab soravtansine and Vascular Biogenics’ VBL-111.

Vaccine Market Size Worth $77.5 Billion By 2024

The global vaccine market size valuation is expected to exceed USD 77.5 billion by 2024, at a CAGR of 10.3% according to a new report by Grand View Research, Inc. The development of various molecules to cater to the growing demand for vaccines can drive market demand. The majority of the key players are focused on vaccine development to gain an edge over competitors. For instance, Pfizer, Inc., is developing vaccines for Clostridium difficile, Staphylococcus aureus, and Meningococcal B.

Furthermore, the broad coalition of governments, worldwide, working to promote the awareness of vaccination benefits through immunization programs with the objective of containing the propagation of communicable diseases that are associated with high morbidity and mortality is expected to stimulate market growth.

For instance, the ‘Immunize Australia Program’ sponsors the immunization of individuals, which acts as a preventative action in preventing disease occurrence and checks rampant disease transmission thus protecting millions of Australians from severe diseases. Another program that has been involved in achieving extensive immunization coverage on the Indian continent is the National Immunization Program, a government program that has focused on taking strong preventive measures to offset vaccine-preventable diseases, particularly in children.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/vaccine-market

Further key findings from the study suggest:

The inactivated vaccine type segment was estimated to have over 14.5% market share in 2015 owing to the related advantages including easy storage and transport due to the highly stable nature of these vaccines. In December 2015, Sanofi Pasteur, Inc. launched a new trivalent, inactivated polio vaccine in India.
The DNA vaccine segment is presumed to be the fastest-growing type over the forecast period owing to the ease of production compared to the cell-based vaccines and the promising, targeted immunization outcomes coupled with the continual developments in the biotechnology area. Other advantages associated are ease of production, long-lasting immunogenicity, and no risk of reversion.
The cancer application segment is expected to witness the fastest growth with a CAGR of over 11.8% in the vaccinations market majorly attributable to the need for immunization against cancer coupled with the increasing prevalence of various types of cancer, such as cervical and colorectal cancers.
North America dominated the market in terms of revenue with over USD 12 billion in 2015, due mainly to the presence of extensive research and development activities and the existence of key participants of the industry in this region
Asia Pacific is identified to witness lucrative growth with a CAGR of around 10.7% during the forecast period due to the growing population base and the increasing economic growth of countries, such as China, Japan, and India. Moreover, the availability of skilled labors at a lower cost and the low manufacturing operations cost provide a platform for clinical trial outsourcing of the vaccinations under development to expedite commercialization.
Leading players in this industry, among others are, Merck & Co., Inc., Emergent BioSolutions, Inc., Johnson and Johnson, Sanofi Pasteur, Inc., Pfizer, Inc., Novartis AG, CSL Ltd., and GlaxoSmithKline Plc. Other prominent players include Abbott Laboratories, Inc., AstraZeneca plc, Janssen Pharmaceuticals, Inc., Takeda Pharmaceuticals Company Ltd., and Valeant Pharmaceuticals International, Inc.
In April 2016, VBI vaccines, Inc. entered into a collaborative agreement with Sanofi Pasteur, Inc. to employ its “Lipid Particle Vaccine” formulation technology to better the stability of the Sanofi vaccines.

Aminoglycoside Market Size To Reach $1.68 Billion By 2022

Global aminoglycoside market is expected to reach USD 1.68 billion by 2022 growing at an estimated CAGR of 3.5% from 2015 to 2022, according to a new report by Grand View Research, Inc. This expected growth in demand can be ascribed to the increasing incidences of animal disease outbreaks leading to high utilization of antibiotics.

However, reduction in prescription rate of aminoglycoside antibiotics due to side effects associated with usage of these drugs that include severe ototoxicity, nephrotoxicity, and neuromuscular blockade are expected to affect the market growth negatively. Furthermore, regulatory disapproval for the usage of certain aminoglycoside in regions is also anticipated to attribute for subordinate growth in this industry.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/aminoglycoside-market

Further key findings from the report suggest:

Neomycin and tobramycin together contributed for over USD 600 million as revenue in this market owing to higher usage and prescription of these drugs for treatment of different bacterial infections. Neomycin finds higher usage in topical formulations for treatment of different skin infections.
Injectables accounted for the largest share of revenue amongst other routes of administration owing to higher usage for treatment of tuberculosis, MDR-TB, and XDR-TB. Use of second line anti tuberculosis drugs such as kanamycin & capreomycin by global organizations is attributive for generation of maximum revenue in this segment.
Human use for treatment of respiratory disorders accounted for largest share in applications segment owing to rise in global incidence of tuberculosis. Furthermore, other bacterial infections of respiratory tract that can be treated using aminoglycoside class of antibiotics are anticipated to contribute for expected growth in this segment.
Veterinary treatment is expected to boost industrial growth in the coming years owing to higher incidence of animal diseases outbreaks. However, these drugs have restrictive regulations for administration to food-producing animals as it may lead to toxic effects and resistance development on humans after consumption of animal originated food.
Asia Pacific was the largest market, accounting for over 40% of revenue in aminoglycoside industry owing to, the presence of market players in this region coupled with higher rate of tuberculosis incidences herein.
South Africa spearheaded growth in the MEA market. The presence of relatively higher demand and consumption of injectable solutions in this region because of increase in incidence rate of MDR-TB and other drug resistant infections are some regional growth drivers.
Key participants of the aminoglycoside market include Vega Pharma Ltd., Kremoint Pharma Pvt. Ltd, Xian Wison Biological Technology Co., Ltd., Jiangxi Bolai Pharmacy Co., Ltd., Medson Pharmaceuticals, Hangzhou Uniwise International Co., Ltd., Yi Chang Veterinary Medicine Factory, HuvePharma, and Medico Remedies Pvt. Ltd.
Market players are involved in the development of products with newer formulations and lesser side effects in order to treat eradicate bacterial infections that are resistant to other class of antibiotics.

Liver Diseases Therapeutics Market Growth By Industry Players Till 2022

The liver diseases therapeutics market had value over USD 7,498.0 million in 2014. The major driving factors are increasing numbers of liver diseases like hepatocellular carcinoma and vast unexploited need of patients with these types of diseases. In addition, increasing geriatric population globally is estimated to augment the market demand in the future period.

Huge expenditure by biotechnology and pharmaceutical industries on R&D and availability of sturdy pipeline are the major expected boosting factors for the growth of liver diseases therapeutics market in future period. Governments’ and big companies’ vaccination program are creating awareness about the illness and prevention is boosting the growth of the market.

The market is bifurcated into products and regions. New products are rapidly being launched boosting the market growth. The growth of the market is boosted by the strategic alliances, joint venture between the major players, and growing awareness of healthcare in the upcoming nations.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/liver-diseases-therapeutics-market

Nonetheless, risks and side effects linked with existing medication & stringent FDA and other norms approved by the government along with accessibility of varying treatment measures perform as barriers to the industry. The market was dominated by the antiviral drug sector with a value over USD 2631 million in revenue terms in 2014.

Rising population with liver diseases due to increasing number of alcohol consumers is estimated to boost the market share. Alternatively, the antiviral drug is estimated to observer profitable raise of over 8.8% from 2015 to 2022. This is due to the occurrence of drugs in the pipeline.

The market is estimated to be at over USD 12095.0 million by 2022. This is going to happen due to the increasing geriatric population, rising liver ailments like hepatocellular and hepatitis carcinoma along with high requirement for programs on vaccination in developing nations and high spending on growing healthcare in the developed nations.

North America is dominating the global market due to academic and research institutions performing studies related to medical trials. North America had more than 39% share of the global market in 2014 and is anticipated to carry on leading till 2022. Asia Pacific had share over USD 1615.5 million in 2014 and is estimated at CAGR over 8.5% in the future.

Few of the major industries are Abbott Laboratories, Gilead Sciences, Astellas Pharma Inc., GlaxoSmithKline plc, Bristol-Mayers Squibb, and Merck & Co., Inc.

Anxiety Disorders & Depression Treatment Market Worth $18.3 Billion By 2025

The global anxiety disorders and depression treatment market is expected to reach a value of USD 18.3 billion by 2025. The rising incidence of depression worldwide is anticipated to drive the market growth in the coming years. Increasing adoption of devices and psychotherapies has resulted in the declining demand for antidepressants in recent years.

The rising geriatric population prone to depression and surging prevalence of anxiety disorders, including phobias and generalized anxiety disorder, are further contributing toward the growing demand for antidepressants to treat mental illnesses over the forecast period. Moreover, the introduction of technologically advanced therapies, such as medical implants used for brain stimulation and virtual reality exposure therapies using smartphone-based applications, furnish patients with innovative treatment alternatives.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/anxiety-disorders-and-depression-treatment-market

Further key findings from the study suggest:

Presently, the antidepressant drugs segment holds the largest revenue share. However, due to the rising occurrence of adverse events associated with these therapeutics, this segment’s growth is expected to wane
Patent expiration of branded medicines and the introduction of generic biosimilars, which are cost-effective, are responsible for the shrinking market of antidepressants
On the other hand, the introduction of new medicines, such as Duloxetine, Fetzima, and Brintellix, is predicted to fuel the demand for therapeutics in the coming years
Furthermore, the personalized therapies and devices segment is expected to register the fastest growth owing to its growing adoption by healthcare professionals as they exert fewer side effects as compared to drugs
Cognitive-behavioral therapy held the majority share in 2015 and is expected to register substantial growth in the coming years owing to the shifting preference of healthcare professionals toward this segment
Transcranial Magnetic Stimulation (TMS) is predicted to witness lucrative growth due to the introduction of technologically advanced devices such as MagVita TMS Therapy System by MagVenture in July 2015 and Brainsway Deep TMS in January 2013
North American regional segment for anxiety disorders and depression treatment reached a saturation level owing to the availability of several medicines and the high prevalence of depressive disorders in this region
Pfizer, Inc.; Eli Lilly and Company;GlaxoSmithKline plc; AstraZeneca; and H. Lundbeck A/S captured a sizable share in 2015 and accounted for more than 60% of the antidepressant drugs vertical
The revenue captured by antidepressants is expected to decrease with generics dominating the market during the forecast period